BACKGROUND & AIMS: Elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) occurs during microsatellite instability (MSI) that is not associated with major defects in DNA mismatch repair (MMR) but rather the reduced (heterogenous) expression of the MMR protein hMSH3; it occurs in sporadic colorectal tumors. We examined the timing of development of EMAST during progression of colorectal neoplasias and looked for correlations between EMAST and clinical and pathology features of tumors. METHODS: We evaluated tumor samples from a cohort of patients that had 24 adenomas and 84 colorectal cancers. EMAST were analyzed after DNA microdissection of matched normal and tumor samples using the polymorphic tetranucleotide microsatellite markers MYCL1, D9S242, D20S85, D8S321, and D20S82; data were compared with clinical and pathology findings. Traditional MSI analysis was performed and hMSH3 expression was measured. RESULTS: Moderately differentiated adenocarcinomas and poorly differentiated adenocarcinomas had higher frequencies of EMAST (56.9% and 40.0%, respectively) than well-differentiated adenocarcinomas (12.5%) or adenomas (33.3%) (P = .040). In endoscopic analysis, ulcerated tumors had a higher frequency of EMAST (52.3%) than flat (44.0%) or protruded tumors (20.0%) (P = .049). In quantification, all tumors with >3 tetranucleotide defects lost MSH3 (>75% of cells); nuclear heterogeneity of hMSH3 occurred more frequently in EMAST-positive (40.0%) than in EMAST-negative tumors (13.2%) (P = .010). CONCLUSIONS: EMAST is acquired during progression of adenoma and well-differentiated carcinomas to moderately and poorly differentiated carcinomas; it correlates with nuclear heterogeneity for hMSH3. Loss of hMSH3 corresponds with multiple tetranucleotide frameshifts. The association between EMAST and ulcerated tumors might result from increased inflammation.
BACKGROUND & AIMS: Elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) occurs during microsatellite instability (MSI) that is not associated with major defects in DNA mismatch repair (MMR) but rather the reduced (heterogenous) expression of the MMR protein hMSH3; it occurs in sporadic colorectal tumors. We examined the timing of development of EMAST during progression of colorectal neoplasias and looked for correlations between EMAST and clinical and pathology features of tumors. METHODS: We evaluated tumor samples from a cohort of patients that had 24 adenomas and 84 colorectal cancers. EMAST were analyzed after DNA microdissection of matched normal and tumor samples using the polymorphic tetranucleotide microsatellite markers MYCL1, D9S242, D20S85, D8S321, and D20S82; data were compared with clinical and pathology findings. Traditional MSI analysis was performed and hMSH3 expression was measured. RESULTS: Moderately differentiated adenocarcinomas and poorly differentiated adenocarcinomas had higher frequencies of EMAST (56.9% and 40.0%, respectively) than well-differentiated adenocarcinomas (12.5%) or adenomas (33.3%) (P = .040). In endoscopic analysis, ulcerated tumors had a higher frequency of EMAST (52.3%) than flat (44.0%) or protruded tumors (20.0%) (P = .049). In quantification, all tumors with >3 tetranucleotide defects lost MSH3 (>75% of cells); nuclear heterogeneity of hMSH3 occurred more frequently in EMAST-positive (40.0%) than in EMAST-negative tumors (13.2%) (P = .010). CONCLUSIONS: EMAST is acquired during progression of adenoma and well-differentiated carcinomas to moderately and poorly differentiated carcinomas; it correlates with nuclear heterogeneity for hMSH3. Loss of hMSH3 corresponds with multiple tetranucleotide frameshifts. The association between EMAST and ulcerated tumors might result from increased inflammation.
Authors: Ajay Goel; Christian N Arnold; Donna Niedzwiecki; Dong K Chang; Luigi Ricciardiello; John M Carethers; Jeannette M Dowell; Linda Wasserman; Carolyn Compton; Robert J Mayer; Monica M Bertagnolli; C Richard Boland Journal: Cancer Res Date: 2003-04-01 Impact factor: 12.701
Authors: L Xu; J Chow; J Bonacum; C Eisenberger; S A Ahrendt; M Spafford; L Wu; S M Lee; S Piantadosi; M S Tockman; D Sidransky; J Jen Journal: Int J Cancer Date: 2001-01-15 Impact factor: 7.396
Authors: Abdel-Rahmene Azzouzi; James W F Catto; Ishtiaq Rehman; Stephane Larre; Morgan Roupret; Kenneth M Feeley; Oliver Cussenot; Mark Meuth; Freddie C Hamdy Journal: BJU Int Date: 2007-01-16 Impact factor: 5.588
Authors: Bikash Devaraj; Aaron Lee; Betty L Cabrera; Katsumi Miyai; Linda Luo; Sonia Ramamoorthy; Temitope Keku; Robert S Sandler; Kathleen L McGuire; John M Carethers Journal: J Gastrointest Surg Date: 2010-09-16 Impact factor: 3.452
Authors: Christina L Chang; Giancarlo Marra; Dharam P Chauhan; Hannah T Ha; Dong K Chang; Luigi Ricciardiello; Ann Randolph; John M Carethers; C Richard Boland Journal: Am J Physiol Cell Physiol Date: 2002-07 Impact factor: 4.249
Authors: Hadi Danaee; Heather H Nelson; Margaret R Karagas; Alan R Schned; Tara Devi S Ashok; Tomoko Hirao; Ann E Perry; Karl T Kelsey Journal: Oncogene Date: 2002-07-25 Impact factor: 9.867
Authors: James W F Catto; Abdel-Rahmene Azzouzi; Najla Amira; Ishtiaq Rehman; Kenneth M Feeley; Simon S Cross; Gaelle Fromont; Mathilde Sibony; Freddie C Hamdy; Oliver Cussenot; Mark Meuth Journal: Oncogene Date: 2003-11-27 Impact factor: 9.867
Authors: J M M van Oers; Y Edwards; R Chahwan; W Zhang; C Smith; X Pechuan; S Schaetzlein; B Jin; Y Wang; A Bergman; M D Scharff; W Edelmann Journal: Oncogene Date: 2013-09-09 Impact factor: 9.867
Authors: Stephanie S Tseng-Rogenski; Koji Munakata; Daniel Y Choi; Paul K Martin; Supal Mehta; Minoru Koi; Wei Zheng; Yang Zhang; John M Carethers Journal: Mol Cell Biol Date: 2020-06-15 Impact factor: 4.272